Matches in Nanopublications for { ?s ?p "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP902185.RAQXZTJi-KmVT12rR7mColpfDiDZXzbCd4BGaBNzs6z5Q130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP902185.RAQXZTJi-KmVT12rR7mColpfDiDZXzbCd4BGaBNzs6z5Q130_provenance.
- NP596374.RA2OVmuMsO1x3YfMotCDS7nonBs3wCR0RAEkWPbltt6iQ130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP596374.RA2OVmuMsO1x3YfMotCDS7nonBs3wCR0RAEkWPbltt6iQ130_provenance.
- NP291003.RAbm2IMNGodpa04V0qQzDQXs-pyeXrZ4Ky8MP2ld1nSUQ130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP291003.RAbm2IMNGodpa04V0qQzDQXs-pyeXrZ4Ky8MP2ld1nSUQ130_provenance.
- assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615661.RAHuXdS95xDI_NgI85fVEK6LeiZyG8Oj78I4tQk1krwvo130_provenance.
- assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP911228.RArR8bOAEfCwQJSRDKyL7e9_QwdWwOK3cxX6h6sT9FroE130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911228.RArR8bOAEfCwQJSRDKyL7e9_QwdWwOK3cxX6h6sT9FroE130_provenance.
- NP791171.RAlj-Xy_VPL8mKW5P87iysFwHKsSi7xO5aKAqh_gE6yJA130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791171.RAlj-Xy_VPL8mKW5P87iysFwHKsSi7xO5aKAqh_gE6yJA130_provenance.
- NP791172.RAwuS4ajPIf16KEdBBn7E2Z-WLuykKgCLtMUl3XoxVQJU130_assertion description "[Despite more rapid onset and higher rate of CR than in other molecular subgroups, CRD was inferior in CCND1 without CD20 myeloma, resembling outcomes in MAF/MAFB and proliferation entities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791172.RAwuS4ajPIf16KEdBBn7E2Z-WLuykKgCLtMUl3XoxVQJU130_provenance.